NCT06802796

Brief Summary

In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 25, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 31, 2025

Completed
Last Updated

January 31, 2025

Status Verified

January 1, 2025

Enrollment Period

4 months

First QC Date

January 25, 2025

Last Update Submit

January 25, 2025

Conditions

Pyelonephritis

Outcome Measures

Primary Outcomes (1)

  • Result of plasma NGAL test

    Result of serum test of NGAL

    One day

Study Arms (2)

Group A :patient with pyelonephritis

patient with pyelonephritis

Diagnostic Test: Plasma NGAL test

Group B :patient without pyelonephritis

patient without pyelonephritis

Diagnostic Test: Plasma NGAL test

Interventions

Plasma NGAL testDIAGNOSTIC_TEST

Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.

Group A :patient with pyelonephritisGroup B :patient without pyelonephritis

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All adult patient had fever due to renal infection

You may qualify if:

  • above 20 years Suspected have pyelonphirtis

You may not qualify if:

  • age below 20

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Elsayed Abdelhalim Elsayed

Zagazig, 44749, Egypt

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Pyelonephritis

Condition Hierarchy (Ancestors)

Nephritis, InterstitialNephritisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPyelitisMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer of urology

Study Record Dates

First Submitted

January 25, 2025

First Posted

January 31, 2025

Study Start

February 1, 2024

Primary Completion

June 1, 2024

Study Completion

June 1, 2024

Last Updated

January 31, 2025

Record last verified: 2025-01

Locations

EG(1)